Table 2.
Experiment 2: incidence and severity of joint sepsis and mortality in mice infected with S. aureus LS-1
|
Day |
Parameter |
S. aureus LS-1-infected mice* |
||||
|---|---|---|---|---|---|---|
|
Control |
2.5 mg kg−1 iclaprim |
5 mg kg−1 iclaprim |
10 mg kg−1 iclaprim |
20 mg kg−1 iclaprim |
||
|
Day 3 |
Incidence of joint sepsis, n/n % |
7/24 (29.2) |
3/16 (18.8) |
1/20 (5.0) |
2/20 (10.0) |
2/20 (10.0) |
|
Severity score, mean |
1.6 |
1.3 |
1.0 |
1.5 |
1.5 |
|
|
Mortality, n/n |
0/6 |
1/5 |
0/5 |
0/5 |
0/5 |
|
|
Day 5 |
Incidence of joint sepsis, n/n % |
9/24 (37.5) |
3/16 (18.8) |
2/20 (10.0) |
3/20 (15.0) |
6/20 (30.0) |
|
Severity score, mean |
1.6 |
1.3 |
1.0 |
1.3 |
1.2 |
|
|
Mortality, n/n |
1/6 |
1/5 |
0/5 |
0/5 |
0/5 |
|
|
Day 7 |
Incidence of joint sepsis, n/n % |
4/12 (33.3) |
1/12 (8.3) |
4/12 (33.3) |
2/16 (12.5) |
5/20 (25.0) |
|
Severity score, mean |
1.4 |
1.0 |
1.0 |
1.5 |
1.6 |
|
|
Mortality, n/n |
4/6 |
2/5 |
2/5 |
1/5 |
0/5 |
|
|
Day 9 |
Incidence of joint sepsis, n/n % |
2/8 (25.0) |
1/8 (12.5) |
4/12 (33.3) |
4/16 (25.0) |
4/20 (20.0) |
|
Severity score, mean |
1.3 |
1.0 |
1.7 |
1.5 |
1.8 |
|
|
Mortality, n/n |
4/6 |
3/5 |
2/5 |
1/5 |
0/5 |
|
|
Day 12 |
Incidence of joint sepsis, n/n % |
2/8 (25.0) |
1/8 (12.5) |
1/12 (8.3) |
4/16 (25.0) |
4/16 (25.0) |
|
Severity score, mean |
1.8 |
2.0 |
2.0 |
1.5 |
2.0 |
|
|
Mortality, n/n |
4/6 |
3/5 |
2/5 |
1/5 |
1/5 |
*The assessment of joints affected and the severity score excludes mice that expired prior to the day of examination.